help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by FAHY, J. V.
Right arrow Articles by ADELMAN, D. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by FAHY, J. V.
Right arrow Articles by ADELMAN, D. C.

Am. J. Respir. Crit. Care Med., Volume 160, Number 3, September 1999, 1023-1027

Effect of Aerosolized Anti-IgE (E25) on Airway Responses to Inhaled Allergen in Asthmatic Subjects

JOHN V. FAHY, DONALD W. COCKCROFT, LOUIS-PHILIPPE BOULET, HOFER H. WONG, FRANCINE DESCHESNES, ELIZABETH E. DAVIS, JANE RUPPEL, JOHN Q. SU, and DANIEL C. ADELMAN

The Cardiovascular Research Institute and the Department of Medicine, University of California, San Francisco, California; Pulmonary Unit, Royal University Hospital, Saskatoon, Saskatchewan, Canada; Centre de Pneumologie, Hospital Laval, Sainte-Foy, Québec, Canada; and Genentech Inc., South San Francisco, California

Intravenous administration of a humanized monoclonal antibody of IgE (E25) attenuates the early and late phase response to inhaled allergen in allergic asthmatic subjects. To test whether direct delivery of E25 to the airway might have the same effect, we conducted a randomized, double-blind, three group study in 33 subjects with mild allergic asthma (20 to 46 yr of age, 21 men, FEV1 > 70% predicted). The airway responses to aerosolized allergen were determined at baseline, after 2 and 8 wk of once daily treatment with aerosolized placebo (n = 11), aerosolized E25 1 mg (n = 12), or aerosolized E25 10 mg (n = 10), and after 4 wk of treatment withdrawal. We found that E25 was detectable in the serum during aerosol treatment, although serum IgE did not change significantly in any of the three groups during treatment. In addition, both doses of E25 were no more effective than placebo in attenuating the early phase responses to allergen at both times during treatment. Although aerosolized E25 was generally well tolerated, one subject receiving aerosolized E25 10 mg daily was found to have serum IgG and IgA antibodies to E25. We conclude that aerosol administration of an anti-IgE monoclonal antibody does not inhibit the airway responses to inhaled allergen in allergic asthmatic subjects. We speculate that the observed lack of efficacy may be due to the inability of aerosol route of delivery to result in high enough concentrations of E25 in the tissue compartments surrounding IgE effector cells to neutralize IgE arising from local airway and pulmonary sources and IgE arising from the vascular space. Additionally, the aerosol route of delivery of monoclonal antibodies may be more immunogenic than the parenteral route.




This article has been cited by other articles:


Home page
 J. Immunol.Home page
C. B. Mathias, E.-J. Freyschmidt, B. Caplan, T. Jones, D. Poddighe, W. Xing, K. L. Harrison, M. F. Gurish, and H. C. Oettgen
IgE Influences the Number and Function of Mature Mast Cells, but Not Progenitor Recruitment in Allergic Pulmonary Inflammation
J. Immunol., February 15, 2009; 182(4): 2416 - 2424.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
K. C. Beier, T. Kallinich, and E. Hamelmann
T-cell co-stimulatory molecules: novel targets for the treatment of allergic airway disease
Eur. Respir. J., August 1, 2007; 30(2): 383 - 390.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
A. D. Kraneveld, M. Kool, A. H. van Houwelingen, P. Roholl, A. Solomon, D. S. Postma, F. P. Nijkamp, and F. A. Redegeld
From The Cover: Elicitation of allergic asthma by immunoglobulin free light chains
PNAS, February 1, 2005; 102(5): 1578 - 1583.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J Douwes, P Gibson, J Pekkanen, and N Pearce
Non-eosinophilic asthma: importance and possible mechanisms
Thorax, July 1, 2002; 57(7): 643 - 648.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
D. R. WILSON, T. G. MERRETT, E. M. VARGA, L. SMURTHWAITE, H. J. GOULD, M. KEMP, J. HOOPER, S. J. TILL, and S. R. DURHAM
Increases in Allergen-Specific IgE in BAL after Segmental Allergen Challenge in Atopic Asthmatics
Am. J. Respir. Crit. Care Med., January 1, 2002; 165(1): 22 - 26.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
W. W. BUSSE
Anti-Immunoglobulin E (Omalizumab) Therapy in Allergic Asthma
Am. J. Respir. Crit. Care Med., October 15, 2001; 164(8): S12 - 17.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
P. J. Barnes
Anti-IgE Antibody Therapy for Asthma
N. Engl. J. Med., December 23, 1999; 341(26): 2006 - 2008.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1999 American Thoracic Society 		  Work-Life